



EXPRESS MAIL MAILING LABEL NO.: EV334240811US

PATENT

Attorney Docket No. INL-053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dai *et al.* CONFIRMATION NO: 3767
SERIAL NO.: 10/029,406 GROUP NO.: 1651
FILING DATE: December 19, 2001 EXAMINER: Saucier, Sandra E.
TITLE: PROTEIN S FUNCTIONAL ASSAY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application.

Inasmuch as the Examiner objected to references C97, C130-C134, and C136-137, submitted on May 31, 2002, and reference C147, submitted on July 25, 2002, for failure to comply with various aspects of 37 C.F.R. 1.98, Applicants resubmit copies of the aforementioned references herewith and therefore, retain the original numbering of the documents on the accompanying Form PTO-1449.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

07/01/2004 MBERHE 00000113 10029406

03 FC:1806

180.00 DP

- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Duan Wu
Attorney for Applicant
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: June 25, 2004
Reg. No. Limited Recognition

Tel. No.: (617) 248-7808
Fax No.: (617) 248-7100



EXPRESS MAIL MAILING LABEL NO.: EV334240811US

SHEET 1 OF 1

FORM PTO - 1449	ATTORNEY DOCKET NO.: INL-053
SIXTH SUPPLEMENTAL INFORMATION	APPLICANT: Dai <i>et al.</i>
DISCLOSURE STATEMENT	SERIAL NO.: 10/029,406
	FILING DATE: December 19, 2001
	GROUP: 1651

U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	C97	Rosén, <i>et al.</i> , "Protein S, an Important Regulatory Protein in Hemostasis," <i>Protein S - Chromogenic Monograph Series</i> 21 pages (Nov. 2000, approximate publication date).						
	C130	Walker, "Protein S and the Regulation of Activated Protein C," <i>Semin. Thromb. Hemost.</i> 10(2):131-138 (1984).						
	C131	Walker, "Regulation of Bovine Activated Protein C By Protein S: The Role of the Cofactor Protein In Species Specificity," <i>Thromb. Res.</i> 22:321-327 (1981).						
	C132	Walker, "Regulation of Activated Protein C by a New Protein," <i>Bio. Chem.</i> 255(12):5521-5524 (1980).						
	C133	Walker, <i>et al.</i> , "The Inhibition of Blood Coagulation by Activated Protein C Through the Selective Inactivation of Activated Factor V," <i>Biochimica et Biophysica Acta</i> 571:333-342 (1979).						
	C134	Wiesel, <i>et al.</i> , "Screening of Protein S Deficiency Using a Functional Assay in Patients with Venous and Arterial Thrombosis," <i>Thromb. Res.</i> 58:461-468 (1990).						
	C136	Wolf, <i>et al.</i> , "Clinical Applications of a Direct Assay of Free Protein S Antigen Using Monoclonal Antibodies. A Study of 59 Cases," <i>Blood Coag. and Fibrin.</i> 5:187-192 (1994).						
	C137	Wolf, <i>et al.</i> , "Functional Assay of Protein S in 70 Patients with Congenital and Acquired Disorders," <i>Blood Coag. and Fibrin.</i> 2:705-712 (1991).						
	C147	Diagnostika Stago, "STACLOT® PROTEIN C Additional Information" 1 page, (Publication date unknown).						

EXAMINER

DATE CONSIDERED

3085641